Literature DB >> 34918530

The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-up.

P Vaňuga1, M Kužma, D Stojkovičová, J Smaha, P Jackuliak, Z Killinger, J Payer.   

Abstract

There are only few studies concerning about long-term effect of growth hormone (GH) replacement therapy on bone mineral density and bone microstructure. To assess effect of GH replacement therapy on bone mineral density (BMD) and trabecular bone score (TBS) in adult GH deficient (AGHD) subjects over period of 10 years. From 2005 to 2018, a prospective study of AGHD patients was conducted in national referral center for treatment of GHD. All patients received subcutaneous recombinant human GH in an IGF 1-normalizing regimen once a day. Lumbar spine (L-spine) and total hip (TH) BMD using Hologic densitometers were measured at baseline and every two years during treatment with rhGH. TBS was derived from L1-L4 DXA using iNsight® software (Medimaps, France) at each time point. Periods of measurement were baseline, year 2; 4; 6; 8 and 10. In total, 63 patients (38 males, 25 females, mean age 25.1±16 years) were included in the study. After 10 years of GH treatment, IGF-1 significantly increased (~35 %), with greatest increase at year 2. During 10-year follow-up, L-spine BMD increased approximately of 7 % (NS). TH BMD increase of 11 % during follow-up (p=0.0003). The greatest increment of BMD was achieved at year 6 on both sites, L-spine (+6 %) and TH BMD (+13 %) (p<0.05). There was no significant change of TBS during whole follow-up. In this study, sustaining positive effect of GH replacement therapy on bone density in subjects with adult GH deficiency over 10 years of follow-up was observed. The study did not show effect on TBS, as indirect measure of trabecular bone microarchitecture.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34918530      PMCID: PMC8884382          DOI: 10.33549/physiolres.934775

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  30 in total

Review 1.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Stephen M Shalet; Mary Lee Vance; Patricia A Stephens
Journal:  J Clin Endocrinol Metab       Date:  2006-04-24       Impact factor: 5.958

2.  The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.

Authors:  G Saggese; G I Baroncelli; S Bertelloni; S Barsanti
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

3.  Impact of the growth hormone replacement on bone status in growth hormone deficient adults.

Authors:  M Kužma; Z Kužmová; Z Zelinková; Z Killinger; P Vaňuga; I Lazurová; S Tomková; J Payer
Journal:  Growth Horm IGF Res       Date:  2013-12-07       Impact factor: 2.372

4.  Determinants of bone microarchitecture and mechanical properties in obese men.

Authors:  Miriam A Bredella; Eleanor Lin; Anu V Gerweck; Melissa G Landa; Bijoy J Thomas; Martin Torriani; Mary L Bouxsein; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2012-08-29       Impact factor: 5.958

5.  Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults.

Authors:  C Clanget; T Seck; V Hinke; C Wüster; R Ziegler; J Pfeilschifter
Journal:  Clin Endocrinol (Oxf)       Date:  2001-07       Impact factor: 3.478

6.  Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men.

Authors:  Nathalie Bravenboer; Paulien J Holzmann; Jan C ter Maaten; Lotte M Stuurman; Jan C Roos; Paul Lips
Journal:  J Bone Miner Res       Date:  2005-06-26       Impact factor: 6.741

7.  Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency.

Authors:  A P Jørgensen; K J Fougner; T Ueland; O Gudmundsen; P Burman; T Schreiner; J Bollerslev
Journal:  Growth Horm IGF Res       Date:  2011-02-03       Impact factor: 2.372

8.  Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study.

Authors:  Natasha M Appelman-Dijkstra; Kim M J A Claessen; Neveen A T Hamdy; Alberto M Pereira; Nienke R Biermasz
Journal:  Clin Endocrinol (Oxf)       Date:  2014-06-05       Impact factor: 3.478

9.  Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.

Authors:  N R Biermasz; N A Hamdy; Y J Janssen; F Roelfsema
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

10.  Cardiovascular risk factors in adult patients with growth hormone deficiency.

Authors:  T Rosén; S Edén; G Larson; L Wilhelmsen; B A Bengtsson
Journal:  Acta Endocrinol (Copenh)       Date:  1993-09
View more
  1 in total

Review 1.  Musculoskeletal Effects of Altered GH Action.

Authors:  Jonathan A Young; Shouan Zhu; Edward O List; Silvana Duran-Ortiz; Yosri Slama; Darlene E Berryman
Journal:  Front Physiol       Date:  2022-05-19       Impact factor: 4.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.